Substance P antagonist MK-869 (L-754,030) will be studied in a Phase III clinical trial for prevention of chemotherapy-induced emesis to begin this year, based on a Phase II trial published in the Jan. 21 New England Journal of Medicine ("The Pink Sheet" May 25, 1998, p. 25). A recent Phase II study in depression was "not definitive due to a high placebo response rate" but suggested activity at one dose, Merck said. The company is evaluating the development of MK-869 for depression and is commencing a Phase II trial for that indication with a backup Substance P antagonist
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
FDA Commissioner Martin Makary suggested 60 new molecular entities could be approved in 2025, which appears possible, but can the strained staff deliver?
PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.
Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.
